Stock Analysis on Net

Amgen Inc. (NASDAQ:AMGN)

Balance Sheet: Assets 

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Amgen Inc., consolidated balance sheet: assets

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Cash and cash equivalents 11,973 10,944 7,629 7,989 6,266
Marketable securities 1,676 48 4,381
Trade receivables, net 6,782 7,268 5,563 4,895 4,525
Inventories 6,998 9,518 4,930 4,086 3,893
Prepaid expenses 2,139 1,647 1,204 1,223 1,156
Corporate partner receivables 521 502 700 780 583
Tax receivables 198 172 129 164 216
Other 419 281 355 200 124
Other current assets 3,277 2,602 2,388 2,367 2,079
Current assets 29,030 30,332 22,186 19,385 21,144
Property, plant and equipment, net 6,543 5,941 5,427 5,184 4,889
Intangible assets, net 27,699 32,641 16,080 15,182 16,587
Goodwill 18,637 18,629 15,529 14,890 14,689
Other noncurrent assets 9,930 9,611 5,899 6,524 5,639
Noncurrent assets 62,809 66,822 42,935 41,780 41,804
Total assets 91,839 97,154 65,121 61,165 62,948

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Assets: Selected Items

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Amgen Inc. current assets increased from 2022 to 2023 but then slightly decreased from 2023 to 2024.
Property, plant and equipment, net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Amgen Inc. property, plant and equipment, net increased from 2022 to 2023 and from 2023 to 2024.
Noncurrent assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Amgen Inc. noncurrent assets increased from 2022 to 2023 but then slightly decreased from 2023 to 2024.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Amgen Inc. total assets increased from 2022 to 2023 but then slightly decreased from 2023 to 2024.

Current Assets: Selected Items

Balance sheet item Description The company
Cash and cash equivalents Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Amgen Inc. cash and cash equivalents increased from 2022 to 2023 and from 2023 to 2024.
Marketable securities Amount of investment in marketable security, classified as current.
Trade receivables, net Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Amgen Inc. trade receivables, net increased from 2022 to 2023 but then slightly decreased from 2023 to 2024.
Inventories Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Amgen Inc. inventories increased from 2022 to 2023 but then slightly decreased from 2023 to 2024 not reaching 2022 level.